<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2854">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472822</url>
  </required_header>
  <id_info>
    <org_study_id>BIOYD-KA-SCHISANDRA</org_study_id>
    <nct_id>NCT01472822</nct_id>
  </id_info>
  <brief_title>Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of Omija Extract on Gonarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee osteoarthritis (KO) is a common arthropathy and a leading cause of disability in
      elderly adults. Schizandra chinensis(Omija) has been known to have five predominant tastes:
      salty, sweet, sour, astringent, and bitter. It has also been shown to have various effects
      on the anti-inflammatory, cardiovascular system, gastrointestinal system, central nervous
      system, endocrine system, and stress protect. Therefore, this study is designed to evaluate
      the efficacy and safety on KO of Omija extract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present study, the investigators will assess the efficacy and safety of the
      formulation of Omija extract(1,200 mg administered twice a day) on the symptoms of knee
      osteoarthritis (KO) during a 12-week treatment course. In a randomized, double-blind
      placebo-controlled trial, subjects will be randomly assign to receive oral omija treatment
      group(n=30) or placebo group(n=30). The primary efficacy outcome measure will be score
      change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) after
      12-weeks. Secondary parameters will be included the Lysholm index score, hs-CRP,
      osteocalcin(OSC), and deoxypyridinoline(DPYR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0-96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Lysholm Index Score</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Lysholm index score total score (score 0-100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OSC(Osteocalcin)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in DPD(Deoxypyridinoline)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Mild Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Omija extract.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omija extract.</intervention_name>
    <description>Omija extract 1.2g/day for 12weeks</description>
    <arm_group_label>Omija extract.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1.2g/day for 12weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 30-70 years old

          -  mild to Moderate KO(Knee Osteoarthritis) as indicated by WOMAC(Western Ontario and
             McMaster University Osteoarthritis Index) score ≥ 38

          -  Able to walk

          -  Subject agrees not to start any new therapies for OA during the course of the study

          -  Able to give informed consent

        Exclusion Criteria:

          -  History of underlying inflammatory arthropathy; septic arthritis; inflammatory joint
             disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia;
             Wilson's disease; ochronosis; haemochromatosis; heritable arthritic disorder or
             collagen gene mutations or rheumatoid arthritis

          -  Expectation of surgery in the next 4 months

          -  Recent injury in the area affected by OA of the knee, i.e. meniscal tear (past 4
             months)

          -  Cartilage reconstruction procedure in the target knee

          -  Intra-articular corticosteroid injections in the target knee within the last 3 months

          -  Viscous injections in the target knee within the last 6 months

          -  Abnormal liver or kidney function tests (ALT or AST &gt; 2 times the upper limit of
             normal; elevated creatinine, males&gt;125 umol/L, females&gt;110 umol/L)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hwan Seo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 27, 2012</lastchanged_date>
  <firstreceived_date>November 14, 2011</firstreceived_date>
  <firstreceived_results_date>July 26, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Omija</keyword>
  <keyword>knee osteoarthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 30 to 70 years, mild to Moderate KO as indicated by WOMAC(Western Ontario and McMaster Universities Arthritis Index) score ≥ 38 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omija Extract.</title>
          <description>Omija extract.(2times/day, 4tablets/day, 1.2g/day) for 12weeks
Omija extract.: Omija extracted with ethanol and then concentrated and dried.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo(2times/day, 4tablets/day, 1.2g/day) for 12weeks
Placebo : Amount and calorie of placebo are same with Omija extract..</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omija</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.1" spread="9.5"/>
                <measurement group_id="B2" value="52.4" spread="9.6"/>
                <measurement group_id="B3" value="52.2" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="55"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</title>
        <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0–96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score</title>
            <description>WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0–96) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).</description>
            <units>Score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 1(0 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.0" spread="11.6"/>
                  <measurement group_id="O2" value="53.3" spread="11.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>visit 3(12 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.8" spread="17.2"/>
                  <measurement group_id="O2" value="31.5" spread="15.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lysholm Index Score</title>
        <description>Lysholm index score total score (score 0–100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Lysholm Index Score</title>
            <description>Lysholm index score total score (score 0–100) was measured in study visit 1(0 week) and visit 3(12 week).
The original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down&amp;up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).</description>
            <units>units on a scale(0-100)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 1(0 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.6" spread="11.0"/>
                  <measurement group_id="O2" value="48.3" spread="13.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 3(12 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.8" spread="10.8"/>
                  <measurement group_id="O2" value="59.9" spread="15.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</title>
        <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</title>
            <description>hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>mg/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 1(0 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="0.4"/>
                  <measurement group_id="O2" value="1.2" spread="4.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 3(12 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.9"/>
                  <measurement group_id="O2" value="0.6" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in OSC(Osteocalcin)</title>
        <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in OSC(Osteocalcin)</title>
            <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 1(0 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.5" spread="6.2"/>
                  <measurement group_id="O2" value="16.6" spread="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 3(12 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.8" spread="5.3"/>
                  <measurement group_id="O2" value="17.3" spread="7.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in DPD(Deoxypyridinoline)</title>
        <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Omija Extract</title>
            <description>Oral intake Omija extract(1.2g/day) for 12weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral intake placebo(1.2g/day) for 12weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Changes in DPD(Deoxypyridinoline)</title>
            <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
            <units>nanoMolar DPD per milliMolar creatine</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 1(0 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.3" spread="2.5"/>
                  <measurement group_id="O2" value="7.2" spread="2.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 3(12 week)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.2" spread="1.9"/>
                  <measurement group_id="O2" value="7.5" spread="2.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Omija</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeong-Hwan Seo, MD</name_or_title>
      <organization>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</organization>
      <phone>82-63-276-8284</phone>
      <email>vivaseo@jbnu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
